Cuál es el precio por Ensysce Biosciences, Inc. (ENSC)

Precio por Ensysce Biosciences, Inc. (ENSC) es de$0.2483

Cuál es la capitalización de mercado por Ensysce Biosciences, Inc. (ENSC)

Capitalización de mercado por Ensysce Biosciences, Inc. (ENSC) es $2.30M

Ganancias de Ensysce Biosciences, Inc. (ENSC)

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.

Año	Ganancias	Cambiar
2026 (TTM)	$-12.62M	58.06%
2024	$-7.99M	-24.84%
2023	$-10.63M	-56.10%
2022	$-24.21M	-16.94%
2021	$-29.15M	18,017.11%
2020	$-160.88K	-98.41%
2019	$-10.10M	-477.51%
2018	$2.68M	-9,810.43%
2017	$-27.56K	0.00%

Año

Ganancias

Cambiar

2026 (TTM)

$-12.62M

58.06%

2024

$-7.99M

-24.84%

2023

$-10.63M

-56.10%

2022

$-24.21M

-16.94%

2021

$-29.15M

18,017.11%

2020

$-160.88K

-98.41%

2019

$-10.10M

-477.51%

2018

$2.68M

-9,810.43%

2017

$-27.56K

0.00%

Empresa	Ganancias	Diferencia de ganancias	País
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-41,883.41%	US
Moderna, Inc. MRNA.US	$-3.09B	24,352.67%	US
Argenx SE ARGX.US	$1.95B	-15,551.44%	NL
CSL Limited CSL.AX	$-4.02B	31,713.00%	AU
Lonza Group AG LONN.SW	-	-	CH

Empresa

Ganancias

Diferencia de ganancias

País